Literature DB >> 22226129

Integrated residency training pathways of the future: diagnostic radiology, nuclear radiology, nuclear medicine, and molecular imaging.

M Elizabeth Oates1.   

Abstract

Following up on the recommendations of the ACR/SNM Task Force on Nuclear Medicine Training, the respective leaderships convened Task Force II. Its charge is to develop realistic residency training pathways integrating diagnostic radiology, nuclear radiology, nuclear medicine, and molecular imaging. The diagnostic radiology participants offer these "pathways of the future" that are built on a foundation of training in diagnostic radiology. It is hoped that these pathways will ensure that the traditional and emerging clinical, educational, and research domains of nuclear radiology, nuclear medicine, and molecular imaging will be sustained and will indeed flourish in the decades to come.
Copyright © 2012 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22226129     DOI: 10.1016/j.jacr.2011.12.017

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  3 in total

Review 1.  A Perspective of the Future of Nuclear Medicine Training and Certification.

Authors:  Julio Arevalo-Perez; Manuel Paris; Michael M Graham; Joseph R Osborne
Journal:  Semin Nucl Med       Date:  2016-01       Impact factor: 4.446

2.  Summary of the First ISMRM-SNMMI Workshop on PET/MRI: Applications and Limitations.

Authors:  Thomas A Hope; Zahi A Fayad; Kathryn J Fowler; Dawn Holley; Andrei Iagaru; Alan B McMillan; Patrick Veit-Haiback; Robert J Witte; Greg Zaharchuk; Ciprian Catana
Journal:  J Nucl Med       Date:  2019-05-23       Impact factor: 10.057

Review 3.  Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective.

Authors:  Antonis Kalemis; Bénédicte M A Delattre; Susanne Heinzer
Journal:  MAGMA       Date:  2012-08-07       Impact factor: 2.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.